nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

15.05.2019 | Image of the Month

Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [¹⁸F]-FDG PET/CT

verfasst von: Aurélie Moreau, Anne Laure Giraudet, Thomas Mognetti, David Kryza

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Excerpt

A patient with metastatic lung adenocarcinoma was placed on immunotherapy with nivolumab. A first [¹⁸F]-FDG PET/CT examination was performed before immunotherapy (a.). Two years after having initiated nivolumab, [¹⁸F]-FDG PET/CT showed an almost complete metabolic response, but revealed the occurrence of a hypermetabolic infiltration surrounding the abdominal artery and primary iliac arteries (b., d.). This raised the potential diagnosis of retroperitoneal fibrosis (RPF) in the specific context of immunotherapy, although the assumptions of lymph node infiltration related to pulmonary adenocarcinoma, or lymphoproliferative syndrome, could not be eliminated. The histologic analysis confirmed the diagnosis of iatrogenic RPF. …

Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 2016;27(7):1880–9.CrossRefPubMedPubMedCentral

Fernández-López R, Lojo JA, Acevedo-Báñez I, González-León R, Borrego-Dorado I. (18)F-FDG PET/CT in patients with idiopathic retroperitoneal and mediastinal fibrosis. Eur J Nucl Med Mol Imaging. 2016;43(9):1739–40.CrossRefPubMed

Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–50.CrossRefPubMed

Fernando A, Pattison J, Horsfield C, D’Cruz D, Cook G, O’Brien T. [18F]-Fluorodeoxyglucose positron emission tomography in the diagnosis, treatment stratification, and monitoring of patients with retroperitoneal fibrosis: a prospective clinical study. Eur Urol. 2017;71(6):926–33.CrossRefPubMed

Titel: Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT
verfasst von: Aurélie Moreau
Anne Laure Giraudet
Thomas Mognetti
David Kryza
Publikationsdatum: 15.05.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04352-1

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group

[18F]FDG PET/CT in non-union: improving the diagnostic performances by using both PET and CT criteria

Ultrafast bone scintigraphy scan for detecting bone metastasis using a CZT whole-body gamma camera

Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas

Andrei Iagaru, Thomas Hope, Patrick Veit-Haibach (Eds): PET/MRI in Oncology. Current Clinical Applications

Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas